- Home
- LNZA vs ICCC Comparison
LNZA vs ICCC Comparison
Compare LNZA & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNZA
- ICCC
- Stock Information
- Founded
- LNZA 2005
- ICCC 1982
- Country
- LNZA United States
- ICCC United States
- Employees
- LNZA N/A
- ICCC N/A
- Industry
- LNZA Major Chemicals
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- LNZA Industrials
- ICCC Health Care
- Exchange
- LNZA Nasdaq
- ICCC Nasdaq
- Market Cap
- LNZA 65.7M
- ICCC 60.1M
- IPO Year
- LNZA N/A
- ICCC 1987
- Fundamental
- Price
- LNZA $0.28
- ICCC $6.39
- Analyst Decision
- LNZA Hold
- ICCC
- Analyst Count
- LNZA 2
- ICCC 0
- Target Price
- LNZA $2.00
- ICCC N/A
- AVG Volume (30 Days)
- LNZA 1.9M
- ICCC 42.7K
- Earning Date
- LNZA 08-07-2025
- ICCC 08-14-2025
- Dividend Yield
- LNZA N/A
- ICCC N/A
- EPS Growth
- LNZA N/A
- ICCC N/A
- EPS
- LNZA N/A
- ICCC N/A
- Revenue
- LNZA $48,831,000.00
- ICCC $27,302,766.00
- Revenue This Year
- LNZA $58.17
- ICCC N/A
- Revenue Next Year
- LNZA $10.92
- ICCC N/A
- P/E Ratio
- LNZA N/A
- ICCC N/A
- Revenue Growth
- LNZA N/A
- ICCC 28.29
- 52 Week Low
- LNZA $0.14
- ICCC $3.34
- 52 Week High
- LNZA $2.74
- ICCC $7.60
- Technical
- Relative Strength Index (RSI)
- LNZA 52.30
- ICCC 54.37
- Support Level
- LNZA $0.25
- ICCC $6.21
- Resistance Level
- LNZA $0.32
- ICCC $6.86
- Average True Range (ATR)
- LNZA 0.04
- ICCC 0.64
- MACD
- LNZA 0.00
- ICCC -0.04
- Stochastic Oscillator
- LNZA 54.30
- ICCC 59.33
About LNZA LanzaTech Global Inc.
LanzaTech Global Inc is a carbon management company transforming waste carbon into sustainable fuels, fabrics, packaging, and nutrition. Its goal is to advance a circular economy where carbon is reused rather than wasted, reducing reliance on virgin fossil resources and supporting supply chain resilience. The company operates in North America, Europe, Middle East, Africa (EMEA), Asia, and Australia.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.